SCHEMBL5945720

SCHEMBL5945720

NS(=O)(=O)c1ccc(NC(=O)c2n[nH]c3ccc(I)cc23)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 4/20 0.71
CSNK2A1 P68400 4/20 0.54
CA1 P00915 5/20 0.51
CA2 P00918 5/20 0.51
CA9 Q16790 4/20 0.51
CA12 O43570 3/20 0.51
CA11 O75493 1/20 0.48
FLT3 P36888 4/20 0.48
CCNA2 P20248 1/20 0.48
CCNA1 P78396 1/20 0.48
DYRK1A Q13627 2/20 0.47
WNT1 P04628 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TTK P33981 2/20 0.46
DYRK3 O43781 1/20 0.45
MAP4K4 O95819 1/20 0.45
CDK1 P06493 1/20 0.45
MARK3 P27448 1/20 0.45
CLK2 P49760 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4524087 0.83 CDK2 (1.00) CDK2CSNK2A1FLT3CCNA2CCNA1
SCHEMBL29843032 0.83 CDK2 (1.00) CDK2CSNK2A1FLT3CCNA2CCNA1
SCHEMBL4520668 0.83 FLT3 (0.55) CDK2CSNK2A1FLT3CCNA2CCNA1
SCHEMBL5945808 0.83 FLT3 (0.70) CDK2CSNK2A1FLT3CCNA2CCNA1
SCHEMBL5945641 0.80 FLT3 (0.48) CDK2CSNK2A1FLT3CCNA2CCNA1
SCHEMBL6534005 0.79 CSNK2A1 (0.48) CDK2CSNK2A1FLT3CCNA2CCNA1
SCHEMBL5945662 0.79 CSNK2A1 (0.76) CDK2CSNK2A1FLT3CCNA2CCNA1
SCHEMBL5945648 0.76 FLT3 (0.50) CDK2CSNK2A1FLT3CCNA2CCNA1
SCHEMBL6221286 0.76 CDK2 (0.65) CDK2CSNK2A1FLT3CCNA2CCNA1
SCHEMBL5945670 0.75 DYRK1A (0.65) CDK2FLT3CCNA2CCNA1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135589-A1 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors ASTEX TECHNOLOGY, INC. (GB) 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135589-A1 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors CCNC, CDK1, CDK7 CDK2 5/4885CSNK2A1 84/4885CA1 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.